BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24472389)

  • 1. Molecular testing in oncology: problems, pitfalls and progress.
    O'Brien CP; Taylor SE; O'Leary JJ; Finn SP
    Lung Cancer; 2014 Mar; 83(3):309-15. PubMed ID: 24472389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing in precision oncology: challenges and opportunities.
    Kruglyak KM; Lin E; Ong FS
    Expert Rev Mol Diagn; 2014 Jul; 14(6):635-7. PubMed ID: 24791810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and opportunities for next-generation sequencing in companion diagnostics.
    Lin E; Chien J; Ong FS; Fan JB
    Expert Rev Mol Diagn; 2015 Feb; 15(2):193-209. PubMed ID: 25249308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine.
    Aftimos PG; Barthelemy P; Awada A
    Discov Med; 2014 Feb; 17(92):81-91. PubMed ID: 24534471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of molecular diagnostics in cancer diagnosis and treatment.
    Ozretić L; Heukamp LC; Odenthal M; Buettner R
    Onkologie; 2012; 35 Suppl 1():8-12. PubMed ID: 22286582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers.
    Vydelingum NA; Sorbara L; Wagner P; Srivastava S
    Expert Rev Mol Diagn; 2013 Jun; 13(5):421-3. PubMed ID: 23782249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of amplicon-based next-generation sequencing in cancer.
    Chang F; Li MM
    Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular diagnostics in pathology].
    Stenzinger A; Penzel R; Endris V; Weichert W
    Dtsch Med Wochenschr; 2013 May; 138(20):1061-8. PubMed ID: 23670263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
    Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
    J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up close and personal: molecular diagnostics in oncology.
    Rye PD; Rittenhouse H; Stigbrand T
    Tumour Biol; 2004; 25(4):217-20. PubMed ID: 15557760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first FDA marketing authorizations of next-generation sequencing technology and tests: challenges, solutions and impact for future assays.
    Bijwaard K; Dickey JS; Kelm K; Težak Ž
    Expert Rev Mol Diagn; 2015 Jan; 15(1):33-40. PubMed ID: 25370936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition.
    Ku CS; Cooper DN; Iacopetta B; Roukos DH
    Clin Genet; 2013 Jan; 83(1):2-6. PubMed ID: 23020236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ
    J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive markers in early research and companion diagnostic developments in oncology.
    Pickl M; Ruge E; Venturi M
    N Biotechnol; 2012 Sep; 29(6):651-5. PubMed ID: 22484859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond.
    Edsjö A; Russnes HG; Lehtiö J; Tamborero D; Hovig E; Stenzinger A; Rosenquist R;
    J Intern Med; 2024 Jun; 295(6):785-803. PubMed ID: 38698538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and opportunities for oncology biomarker discovery.
    Deyati A; Younesi E; Hofmann-Apitius M; Novac N
    Drug Discov Today; 2013 Jul; 18(13-14):614-24. PubMed ID: 23280501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.